Table 1 Baseline characteristics of study participants.
Clinical characteristics | n = 116 |
|---|---|
Age, years | 59.6 ± 11.4 |
Male | 78 (67.2) |
BW, kg | 72.3 ± 13.3 |
BH, cm | 165.4 ± 9.2 |
BMI, kg/m2 | 26.3 ± 3.6 |
Smoking | 34 (29.3) |
CHADS2-Vasc score | 1.9 ± 1.5 |
Congestive heart failure | 15 (12.9) |
NYHA Fc | |
I | 6 (5.2) |
II | 6 (5.2) |
III | 3 (2.6) |
IV | 0 |
Hypertension | 60 (51.7) |
Diabetes mellitus | 29 (25.0) |
Cerebral vascular accidence/TIA | 11 (9.5) |
Coronary artery disease | 8 (6.9) |
Peripheral artery disease | 0 |
Chronic kidney disease | 12 (10.3) |
End stage renal disease | 3 (2.6) |
Classification of atrial fibrillation | |
Paroxysmal atrial fibrillation | 76 (65) |
Persistent atrial fibrillation | 40 (35) |
Type of procedure | |
Radiofrequency catheter ablation | 82 (70.7) |
Cryoballoon ablation | 22 (19.0) |
Cardioversion | 12 (10.3) |
Pharmacologic therapy | |
Beta-blockers | 78 (67.2) |
ACEi/ARB | 46 (39.7) |
Calcium channel blockers | 27 (23.3) |
Diuretics | 30 (25.9) |
Amiodarone | 68 (58.6) |
Propafenone | 47 (40.5) |
Dronedarone | 3 (2.6) |
Sotalol | 4 (3.4) |
Flecainide | 11 (9.5) |
Digoxin | 3 (2.6) |
